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PTEN is a frequently mutated tumor suppressor
gene that opposes the PI3K/AKT pathway through
dephosphorylation of phosphoinositide-3,4,5-tri-
phosphate. Recently, nuclear compartmentalization
of PTEN was found as a key component of its
tumor-suppressive activity; however its nuclear
function remains poorly defined. Here we show that
nuclear PTEN interactswith APC/C, promotes APC/C
association with CDH1, and thereby enhances the
tumor-suppressive activity of the APC-CDH1 com-
plex.We find that nuclear exclusion but not phospha-
tase inactivation of PTEN impairs APC-CDH1. This
nuclear function of PTEN provides a straightforward
mechanistic explanation for the fail-safe cellular
senescence response elicited by acute PTEN loss
and the tumor-suppressive activity of catalytically
inactive PTEN. Importantly, we demonstrate that
PTEN mutant and PTEN null states are not synony-
mous as they are differentially sensitive to pharma-
cological inhibition of APC-CDH1 targets such as
PLK1 and Aurora kinases. This finding identifies
a strategy for cancer patient stratification and, thus,
optimization of targeted therapies.
INTRODUCTION
PTEN (phosphatase and tensin homolog) is among the most
frequently lost or mutated tumor suppressors, with a frequency
of monoallelic mutations estimated at 50%–80% in endometrial
carcinoma, glioblastoma, and prostate cancer and at 30%–50%
in breast, colon, and lung tumors (Cairns et al., 1997; Feilotter
et al., 1998; Gray et al., 1998; Li and Sun, 1997; Steck et al.,
1997). Complete loss ofPTEN is observed at highest frequencies
in endometrial cancer and glioblastoma and is generally associ-
ated with metastatic cancers (Ali et al., 1999; Salmena et al.,2008). Moreover, germline mutations of PTEN have been
identified in cancer-susceptibility syndromes such as Cowden
syndrome (Di Cristofano et al., 1998; Eng, 2003).
PTEN can dephosphorylate phosphoinositide-3,4,5-triphos-
phate (PIP3), a potent activator of AKT (Maehama and Dixon,
1998). Loss of PTEN function leads to derepression of the
PI3K/AKT pathway, which stimulates cell growth and survival
(Stambolic et al., 1998; Sun et al., 1999). However, emerging
evidence suggests that PTEN also has PI3K/AKT-independent
functions (Salmena et al., 2008). Furthermore, cells harboring
phosphatase-inactive PTEN mutants retain residual tumor-
suppressive activity, leading to the hypothesis that PTEN exerts
functions that are independent of its phosphatase activity
(Blanco-Aparicio et al., 2007; Georgescu et al., 2000; Gildea
et al., 2004; Koul et al., 2002; Maier et al., 1999).
Early studies proposed that PTEN was exclusively cyto-
plasmic. However, recent reports clearly demonstrate that
nuclear PTEN has important tumor-suppressive function (Frid-
berg et al., 2007; Perren et al., 2000; Whiteman et al., 2002;
Zhou et al., 2002). Mechanistically, we have reported that ubiq-
uitination of PTEN regulates its nuclear compartmentalization
(Song et al., 2008; Trotman et al., 2007). However, the tumor-
suppressive functions of PTEN within the nucleus still remain
poorly defined.
Cell-cycle progression is controlled by ubiquitination-medi-
ated proteolysis of cell-cycle machinery. The two major E3 ubiq-
uitin ligases controlling this process are SCF (Skp1/Cullin/F-box
protein complex) and APC/C (anaphase-promoting complex/
cyclosome). SCF mainly controls target protein levels during S
phase, whereas APC/C is thought to be active from mitosis to
late G1 (Cardozo and Pagano, 2004; Peters, 2006). APC/C
contains at least 11 different structural subunits, and its activity
is controlled through the binding of CDC20 and CDH1, which
recognize and recruit specific substrates. CDC20 is active in
early mitosis whereas CDH1 activity is restricted to late mitosis
and G1 (Pines, 2006; Sullivan and Morgan, 2007). Specific
APC/C substrates include mitotic cyclins (Cyclins A and B),
mitotic kinases (Aurora kinases, PLK1, Nek2A), proteins
involved in chromosome segregation (Securin, Sgo1), DNACell 144, 187–199, January 21, 2011 ª2011 Elsevier Inc. 187
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B Figure 1. Nuclear PTEN Interacts with
APC/C
(A) Nuclear extracts fromPTEN-deficient PC3 cells
transfected with Myc-PTEN were immunoprecipi-
tated with an anti-Myc antibody followed by
mass-spectrometric peptide sequencing. APC/C
components including APC3, APC4, APC5, and
APC7 were identified.
(B) DU145 cell lysates were immunoprecipitated
(IP) without (Mock) or with anti-PTEN (left) or anti-
APC3 (right) antibody followed by immunoblotting.
Asterisk indicates heavy chain of IgG.
(C) Recombinant GST-PTEN (aa 1–403), GST-
PTEN-DC (aa 1–185), or GST-PTEN-DN (aa 185–
403) proteins, as shown in left diagram, were
incubated with immunopurified APC/C from PC3
cells released 3 hr from nocodazole synchroniza-
tion. * and # indicate heavy chain of IgG and
nonspecific band, respectively.
(D) Lysates from 12 hr after tetracyclin induction as
in (E) were immunoprecipitated (IP) with anti-PTEN
antibody and subjected to in vitro ubiquitination
assay using 35S-labeled Cyclin B (WT and
destruction box mutant [DBM]) in the presence of
GST-CDH1 protein (50 ng) and immunoblotting
with anti-polyubiquitinated proteins antibody.
(E) PC3 cells were cotransfectedwith pcDNA4/TO/
Myc-His-PTEN and pcDNA6/TR to induce PTEN
expression after the addition of tetracycline (Tet-
on) for the indicated times or treated with 10 mM
MG132 after 8 hr Tet induction for additional 4 hr,
then subjected to immunoblotting (top) and flow
cytometric analysis (bottom). The quantification of
the relative immunoreactivity of each protein
normalized to Actin is represented as the mean
and the standard error of the mean (SEM) from
three different experiments.
(F) Accumulation of APC-CDH1 targets in
PtenloxP/loxP;Probasin-Cre4 (Ptenpc/) mouse
prostate epithelium. Lysates from anterior pros-
tates in wild-type (WT-Cre) and Ptenpc/ mice at
11 weeks age were subjected to immunoblotting.
See also Figures S1A–S1F.replication proteins (Geminin, Cdc6), an F-box protein (SKP2),
and transcription factors (Ets2, FoxM1) (Manchado et al., 2010;
Wasch et al., 2010).
Of importance, APC-CDH1 substrates, such as Cyclin A,
PLK1, Aurora A, CDC20, or SKP2, are overexpressed in human
tumors and are associated with chromosomal instability and
poor prognosis (Carter et al., 2006). In mice, Cdh1 heterozy-
gosity results in the development of epithelial tumors, sug-
gesting that CDH1 may be a haploinsufficient tumor suppressor
(Garcia-Higuera et al., 2008). Downregulation of CDH1 has
been reported in many cancers, including those of prostate,
ovary, liver, and brain, and during the malignant progression
of a B-lymphoma cell line (Bassermann et al., 2008; Wang
et al., 2000). Therefore, inactivation of APC-CDH1 in cancer
may lead to unchecked accumulation of its targets with
profound consequences for cell-cycle and genomic stability.188 Cell 144, 187–199, January 21, 2011 ª2011 Elsevier Inc.In this study, we demonstrate that nuclear PTEN directly
enhances the activity of APC/C by promoting its association
with CDH1. Conversely, PTEN loss impairs the activity of the
APC-CDH1 tumor-suppressive complex. Critically, PTEN acti-
vates APC-CDH1 in a phosphatase-independent manner, an
observation that has important implications for cancer therapy.
RESULTS
Nuclear PTEN Interacts with APC/C
In order to identify novel tumor-suppressive pathways regu-
lated by PTEN, we immunoprecipitated exogenous Myc-
tagged PTEN from the nuclear extracts of PTEN-deficient
PC3 cells and identified interacting proteins by mass spec-
trometry (Figure 1A and Figure S1A available online). Remark-
ably, four APC/C constituents including APC3/CDC27, APC4,
APC5,and APC7 were identified as nuclear PTEN-associated
proteins. We validated the binding between endogenous
PTEN and the four APC/C components in DU145 cells by
performing reciprocal immunoprecipitations (Figure 1B) and
observed that the binding was restricted to the nucleus (Figures
S1B and S1C). Notably, an in vitro binding assay revealed that
the interaction of PTEN with APC3 is restricted to the COOH
terminus of PTEN, indicating that the N-terminal phosphatase
domain is dispensable for this interaction (Figure 1C). Critically,
PTEN immunoprecipitation complexes displayed ubiquitinating
ability toward the well-established APC/C target Cyclin B
(Figure 1D).
We next assessed the functional relevance of this physical
interaction. To test whether PTEN directly affects the levels of
APC/C targets, we developed a model system in which we
could dissociate the consequences of acute PTEN induction
from the ensuing cell-cycle effects. For this we used a Tetracy-
clin-inducible (Tet-on)-PTEN cellular system in asynchronously
growing PC3 cells (Rubin et al., 1991). In this cellular system,
acute PTEN induction precedes any sizable effects on cell-cycle
distribution for at least 12 hr (Figure 1E). By contrast, in this
timeframe PTEN induction led to a marked and rapid protea-
some-dependent downregulation of APC/C targets. This was
reverted by MG132 treatment, at time points much earlier
than any detectable effect on cell-cycle distribution (Figure 1E).
Moreover, we found that APC/CDH1 target levels were
increased in vivo in Pten null prostates at time points where
the incidence of prostate intraepithelial neoplasia (PIN) and
the increase of cell proliferation are low (Figure 1F, Figure S1D,
and data not shown). Similarly, PTEN silencing in DU145
cells led to the upregulation of the APC/C targets, Cyclin A2,
Geminin, PLK1, Aurora A, and CDC20, whereas overexpression
of PTEN in PTEN-deficient LNCaP and PC3 cells reduced
APC/C target levels concomitant with G1 cell-cycle arrest
(Figures S1E and S1F).
Nuclear PTEN Enhances the Activity of APC-CDH1
Our data show that PTEN interacts with components of the
APC/C complex and PTEN status alters the level of APC/C
complex target proteins. Thus, we hypothesized that PTEN can
regulate the ubiquitin ligase activity of APC/C. Indeed, in vitro
APC/C ubiquitin ligase assays revealed that Cyclin B ubiquitina-
tion by APC/C was increased in a dose-dependent manner by
recombinant PTEN protein in the presence of CDH1 (Figure 2A).
By contrast, the ubiquitin ligase activity of APC/C was reduced
in Pten/ mouse embryonic fibroblasts (MEFs) compared to
wild-type cells (Figure 2B). Remarkably, nuclear but not cyto-
plasmic PTEN immunoprecipitates were capable of ubiquitinat-
ing Cyclin B (Figure 2C).
Next, we sought to ascertain the mechanism by which PTEN
regulates APC/C function. APC/C activation occurs upon the
association with two different adaptor proteins, CDC20 and
CDH1 (Cardozo and Pagano, 2004; Peters, 2006). Whereas
CDC20 activates APC/C in early mitosis, APC-CDH1 is active
in late mitosis and during G1 (Pines, 2006; Sullivan and
Morgan, 2007). In vitro Cyclin B ubiquitination assays revealed
that the ubiquitin ligase activity of PTEN immunoprecipitates in
interphase was higher than in mitosis (Figure S1G). We there-fore examined whether PTEN regulates the formation of the
APC-CDH1 complex. In vivo, reintroduction of PTEN into PC3
cells increased the association between APC3 and CDH1 (Fig-
ure 2D, top panel), whereas PTEN knockdown in DU145
dramatically reduced the coimmunoprecipitation of APC3
and CDH1 (Figure 2D, bottom panel). In vitro binding assay
revealed that PTEN favors the assembly between APC3
and CDH1 in a dose-dependent manner (Figure 2E). Taken
together, these results suggest that PTEN promotes the asso-
ciation between APC and CDH1, thereby enhancing the activity
of APC-CDH1.
Nuclear Exclusion of PTEN Impairs Activation
of APC-CDH1
Despite the increasing number of studies emphasizing the
importance of nuclear PTEN as a tumor suppressor (Planchon
et al., 2008; Salmena et al., 2008), how nuclear PTEN exerts its
tumor-suppressive activity remains unclear. We have demon-
strated that PTEN monoubiquitination at lysines 13 and 289 is
essential for its nuclear localization and tumor-suppressive func-
tion, and conversely, deubiquitination of PTEN by HAUSP
renders PTEN predominantly cytoplasmic (Song et al., 2008;
Trotman et al., 2007). Therefore, we tested whether a nuclear-
excluded PTENK13,289E mutant (Figure 3A) could still regulate
APC-CDH1. In vivo ubiquitination assay showed that, unlike
wild-type PTEN, nuclear-excluded PTENK13,289E was unable to
promote the Cyclin B ubiquitination and to reduce the level of
APC-CDH1 targets despite antagonizing AKT activation (Fig-
ure 3B and Figure S2A). Importantly, coimmunoprecipitation
analysis revealed that PTENK13,289E mutant failed to interact
with APC3 (Figure 3C). Because both PTEN and APC-CDH1
are known negative regulators of cell proliferation (Salmena
et al., 2008; Wasch et al., 2010), we next examined the effects
of nuclear exclusion of PTEN on cell growth. BrdU incorporation
analysis revealed that nuclear-excluded PTENK13,289E mutant
was ineffective in suppressing S phase entry after release from
nocodazole block, whereas PTENWT significantly delayed the
G1-S transition accompanied with a reduction in the level of
APC-CDH1 targets (Figure 3D and Figure S2B). This observation
is of critical relevance as it allowed us to uncouple the effect of
PTEN on Akt and APC-CDH1 toward cell-cycle regulation. In
line with this notion, PTENWT but not PTENK13,289E overexpres-
sion led to a downregulation of CDK2 activity due to reduction
in the level of Cyclin A2 rather thanCyclin E at theG1-S transition,
suggesting that nuclear PTEN might regulate the G1-S transition
through reduction in the level of Cyclin A2, an APC-CDH1 target
(Figure 3E). We also ascertained whether the delay in S phase
entry by PTEN could be due to failure to be released from the
nocodazole block or to exit from mitosis. PTENK13,289E as well
as PTENWT overexpression had little impact on mitotic exit, as
measured by the positivity of phospho-histone H3 (Figures
S2C and S2D). In addition, PTENWT- or PTENK13,289E-expressing
PC3 cells exhibited similar proportions of cells in mitosis upon
nocodazole block, suggesting that PTEN might not be involved
in spindle checkpoint (SAC) as well. Taken together, these
results suggest that nuclear localization of PTEN is necessary
for activation of APC-CDH1, thereby regulating cell-cycle
progression.Cell 144, 187–199, January 21, 2011 ª2011 Elsevier Inc. 189
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Figure 2. Nuclear PTEN Regulates the
Activity of APC-CDH1
(A) Immunopurified APC/C from PC3 cells,
released 3 hr post-nocodazole synchronization,
were subjected to in vitro ubiquitination assay
using 35S-labeled in vitro-translated (IVT) wild-type
or DBMCyclin B in the presence of IVT-CDH1 (1 ml)
and different amounts of GST-PTEN proteins
(0, 50, 100 ng) and immunoblotting with anti-
polyubiquitinated protein antibody. Bottom panel
illustrates the density unit (D.U.) of Cyclin B-Ub
conjugates analyzed by the ImageJ 1.383 soft-
ware (NIH). Asterisk indicates nonspecific band.
(B) Lysates from wild-type and Pten/ MEFs
subjected to 48 hr of serum depletion were
immunoprecipitated (IP) with anti-APC3 or anti-
Pten antibody and subjected to in vitro ubiquiti-
nation assay using 35S-labeled Cyclin B in the
presence of GST-CDH1 protein (50 ng). Top panel
shows the density unit (D.U.) of Cyclin B-Ub
conjugates analyzed by the ImageJ 1.383 soft-
ware.
(C) Cytoplasmic (C) and nuclear (N) extracts from
DU145 cells, released 3 hr from nocodazole
synchronization, were IP with anti-APC3 or anti-
PTEN antibody and subjected to in vitro ubiquiti-
nation assay using 35S-labeled Cyclin B. Top panel
shows the density unit (D.U.) of Cyclin B-Ub
conjugates analyzed by the ImageJ 1.383 soft-
ware.
(D) Lysates from PTEN-deficient PC3 cells com-
plemented with empty vector or PTEN (top) or
PTEN-proficient DU145 cells transfected with
siRNAs for Renilla luciferase (siControl) or PTEN
(siPTEN-1) (bottom) were IP with anti-CDH1 anti-
body and then subjected to immunoblotting.
(E) Immunopurified APC/C from PC3 cells,
released 3 hr from nocodazole synchronization,
were incubated with GST-CDH1 (100 ng) and
different amounts of His6-PTEN proteins (0, 50,
100, 200 ng) for 1 hr followed by immunoblotting.
See also Figure S1G.Growth-Suppressive Activity of PTEN Requires
APC-CDH1
Next, we examined the requirement of APC-CDH1 function in
PTEN-mediated cell growth suppression. The effects of PTEN
on cell-cycle distribution as well as APC-CDH1 target modula-
tion were completely abrogated by depletion of APC3 or CDH1
(Figures 4A and 4B). We then evaluated the contribution of
APC-CDH1 to the growth-suppressive function of PTEN by using
wild-type and Cdh1/ MEFs (among which the phosphatase
activity of endogenous Pten was indistinguishable; Figure 4C).
Strikingly, whereas PTEN overexpression induced a growth inhi-
bition in immortalizedCdh1+/+ cells (or inCdh1/MEFs comple-
mented with human CDH1), Cdh1/ cells were refractory to this
effect of PTEN overexpression (Figure 4D, top panel). Consistent
with these data, overexpression of PTEN was accompanied by
the downregulation of Cyclin A2-associated CDK2 activity as190 Cell 144, 187–199, January 21, 2011 ª2011 Elsevier Inc.well as other APC-CDH1 targets in Cdh1+/+ (or in Cdh1/
MEFs complemented with CDH1) but not in Cdh1/ cells (Fig-
ure 4D, bottom panel and Figure S3A). Conversely, the increase
in proliferation and elevation of the level of APC-CDH1 targets
induced by Pten silencing was abrogated in the absence of
Cdh1 (Figure 4E and Figure S3B). Taken together, these results
suggest that the growth-suppressive activity of PTEN is, at least
in part, mediated by APC-CDH1.
PTEN-Loss-Induced Cellular Senescence Involves
APC-CDH1
Reduction of cellular levels of PTEN or CDH1 results in the
decrease of their respective tumor-suppressive activity (Di Cris-
tofano et al., 1998; Garcia-Higuera et al., 2008). However, acute
and complete loss of both Pten and Cdh1 leads to a fail-safe
cellular senescence response; this phenomenon has been
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Figure 3. Nuclear Exclusion of PTEN
Impairs Activation of APC-CDH1
(A) Immunofluorescence analysis of GFP, GFP-
tagged wild-type PTEN (PTENWT), and nuclear-
excluded PTEN mutant (PTENK13,289E). Arrows
indicate the nucleus in PC3 cells.
(B) PC3 cells were cotransfected with a combina-
tion of wild-type or DBM Myc-Cyclin B, HA-ubiq-
uitin (Ub), GFP, PTENWT, and PTENK13,289E and
treated with the proteasome inhibitor MG132
(10 mM) for 4 hr before harvesting. Cell lysates were
then immunoprecipitated (IP) with anti-Myc anti-
body and subjected to immunoblotting (IB). * and #
indicate heavy chain of IgG and nonspecific band,
respectively.
(C) Lysates from PC3 cells transfected with GFP,
PTENWT, or PTENK13,289E were IP with anti-GFP
antibody and subjected to immunoblotting.
(D) PC3 cells transfected with GFP, PTENWT, or
PTENK13,289E were synchronized by growth in no-
codazole (400 nM) for 24 hr, released for the indi-
cated times, pulsed with BrdU for 30 min, and
subjected to flow cytometric analysis. Data are the
means from three different experiments and error
bars represent the SEM.
(E) Lysates from (D) were subjected to in vitro
kinase assay with CDK2, Cyclin E1, or Cyclin A2.
The relative kinase activities were normalized with
histone H1 inputs. Asterisks indicate heavy chain
of IgG.
See also Figure S2. p value was determined by
Student’s t test (*p < 0.01).shown to profoundly suppress tumor progression uponPten loss
(Chen et al., 2005; Li et al., 2008).We therefore hypothesized that
Pten-loss-induced senescence could be in part mediated by
a reduction of Cdh1 activity toward mediators of cellular senes-
cence. In order to test this hypothesis, we overexpressed CDH1
concomitantly with the acute inactivation of Pten in Ptenlox/lox
MEFs. Strikingly, overexpression of CDH1 counteracted the
senescence response (Figures 5A and 5B). Importantly, overex-
pression of CDH1 specifically prevented the increase of p16
mRNA and protein levels, but not those of Arf or p53 (Figures
5C and 5D and Figure S4A). Conversely, complete concomitant
inactivation of Cdh1 and Pten in MEFs dramatically increased
the distinctive morphology of senescent cells (flattened large
cells; data not shown) and the positivity for senescence-associ-
ated b-galactosidase (SA-b-Gal), a hallmark of senescent
cells (Figure 5E and Figure S4B). Consistent with these data,
complete loss of Cdh1 upon Pten loss led to reduced prolifera-
tion compared to Pten loss alone, asmeasured by growth curves
and BrdU incorporation analysis (Figure 5F). Of note, the senes-
cence response elicited upon acute loss of Pten was accompa-
nied by elevation of p19ARF(Arf)/p53/p21 aswell as p16INK4A(p16)
(Figures 5C and 5G). We have previously reported that senes-
cence elicited by acute loss of Pten is accompanied by the acti-Cell 144, 187–199vation of the p53 pathway (Chen et al.,
2005). Interestingly, complete loss of
Cdh1 and Pten led to a dramatic accumu-
lation of p16, whereas Arf or p53/p21 wasnot affected compared to Pten loss alone. Critically, silencing of
p16 prevented Pten-loss-induced senescence without affecting
the p53 axis (Figures S4C–S4E). In line with previous reports
from our lab, p19 silencing also reduced cellular senescence in
Pten null MEFs without affecting p53 (Figures S4C–S4E) (Chen
et al., 2009). As Ets2 has been shown to selectively regulate
p16, but not Arf transcription (Huot et al., 2002; Ohtani et al.,
2001), we analyzed Ets2 levels in Pten null cells to determine
whether an increase in Ets2 could account for the enhanced
expression of p16. Indeed, Ets2 protein but not mRNA level
was markedly upregulated by acute loss of Pten (Figures 5C
and 5G and Figure S4F). Of interest, consistent with the notion
that APC-CDH1 regulates the ubiquitination-mediated degrada-
tion of Ets2 (Figure S4G) (Li et al., 2008), PTEN promoted the
ubiquitination of wild-type but not destruction box mutated
(DBM) Ets2 (Figure 5H). To determine the direct role of the
Ets2/p16 pathway on active senescence in Pten null cells, we
overexpressed or silenced Ets2 upon acute Pten loss. Overex-
pression of DBM Ets2 significantly promoted the senescence
response by Pten loss even in the presence of CDH1 (Figure 5I),
whereas silencing of Ets2 dramatically reduced senescence and
the transcriptional induction of p16 (Figures S4H and S4I).
Collectively, these data provide a compelling mechanism for, January 21, 2011 ª2011 Elsevier Inc. 191
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Figure 4. Growth Suppression by PTEN
Relies on APC-CDH1 Function
(A and B) PC3 cells cotransfected with empty
vector or HA-PTEN and Renilla luciferase siRNA
(siControl), two independent APC3 siRNAs
(siAPC3-1 and -2) (A), or CDH1 siRNAs (siCDH1-1
and -2) (B) were subjected to immunoblotting (top)
and flow cytometric analysis to measure cell-cycle
distribution (bottom). The relative immunoreac-
tivity of each protein was quantified by normalizing
with Hsp90.
(C) diC8-PtdIns(3,4,5)P3 (40 mM) was incubated
with and without (control) the immunopurified Pten
(1 mg) at 37C for 30 min. The amount of free
phosphate was measured as Absorbance 620 nm
(A620nm) and calculated using the standard curve
line-fit data in top panel. Error bars represent SEM
from three different experiments.
(D) Growth curves (top) and in vitro kinase assay
(bottom) of SV40-LT-immortalized wild-type and
Cdh1/ MEFs, infected with a retroviral combi-
nation of human CDH1 and PTEN (with selection)
as indicated and followed over a 3 day period.
Error bars represent the SEM from three different
experiments. Asterisks indicate heavy chain of
IgG.
(E) Growth curves (top) and in vitro kinase assay
(bottom) of immortalized wild-type and Cdh1/
MEFs, infected with a retroviral combination of
human CDH1 and Pten shRNA (with selection) as
indicated and followed over a 3 day period. Error
bars represent SEM from three different experi-
ments. The relative kinase activities were normal-
ized with histone H1 inputs. Asterisks indicate
heavy chain of IgG.
See also Figure S3.the senescence response elicited by Pten loss through parallel
CDH1/Ets2/p16 and Arf or p53/p21.
PTEN Regulates APC-CDH1 Independently
of Its Phosphatase Activity
PTEN opposes the PI3K/AKT signaling pathway by catalyzing
the dephosphorylation of PIP3 (Maehama and Dixon, 1998).
Loss of PTEN leads to the activation of the PI3K/AKT cascade
and stimulates cell growth and survival (Stambolic et al., 1998;
Sun et al., 1999). Nevertheless, cells harboring phosphatase-
inactive PTEN mutants are phenotypically distinct from cells
lacking PTEN protein, suggesting that PTEN exerts functions
that are independent of its phosphatase activity (Blanco-Apari-
cio et al., 2007; Georgescu et al., 2000; Gildea et al., 2004; Maier
et al., 1999; Okumura et al., 2005). In order to examine the contri-
bution of the phosphatase activity of PTEN in the regulation of
APC-CDH1, we first complemented PTEN null PC3 cells, with
either wild-type or phosphatase-inactive PTEN (C124S or
G129E) (Figure 6A). The levels of several canonical APC-CDH1192 Cell 144, 187–199, January 21, 2011 ª2011 Elsevier Inc.targets were reduced upon expression
of PTEN(C124S) or PTEN(G129E) phos-
phatase-inactive mutants in this system
(Figure S5A). Consistently, expression of
phosphatase-inactive PTEN(C124S) inPC3 cells resulted in a delayed entry into S phase, a phenotype
similar to that in wild-type PTEN-expressing PC3 cells or PTEN-
proficient DU145 cells, implying that PTEN regulates the G1-S
transition independent of its phosphatase activity (Figure 6B
and Figures S5B and S5C). Importantly, expression of wild-
type or PTEN(C124S) led to reduced Cyclin A2-associated
CDK2 activity in PC3 cells, suggesting that PTEN(C124S) as
well as wild-type PTEN suppresses the G1-S transition, at least
in part, through APC-CDH1. Consistent with these data, in vivo
xenograft generation with these variants of PC3 cells revealed
a significant growth-suppressive activity of PTEN(C124S), in
line with the modulation of APC-CDH1 targets (Figure 6C).
Although expression of PTEN(C124S) led to a significant reduc-
tion in the level of late mitotic substrates of APC-CDH1, such as
Aurora A, PLK1, and CDC20, the length of mitosis was not signif-
icantly shortened, compared to parental PC3 cells (Figures S5D
and S5E). Importantly, phosphatase-inactive PTEN(C124S)
mutants exhibited comparable activity to wild-type PTEN,
enhancing the ubiquitin ligase activity of APC-CDH1 in vitro (as
AD
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Figure 5. Pten-Loss-Induced Cellular Senescence Involves APC-CDH1
(A–C) Cellular senescence assay (A), growth curves and BrdU incorporation assay (B), and immunoblot (C) of primary Ptenlox/loxMEFs, infected with retroviral Cre
and human CDH1 selected for 4 days. Error bars represent SEM from three different experiments. p value was determined by Student’s t test.
(D) Real-time RT-PCR analysis of murine p16 expression was quantified. Error bars represent SEM.
(E–G) Cellular senescence assay (E), growth curves and BrdU incorporation assay (F), and immunoblotting (G) of primary conditional Ptenlox/lox;Cdh1+/+,
Ptenlox/lox;Cdh1lox/+, Ptenlox/lox;Cdh1lox/loxMEFs, infected with retroviral Cre recombinase at 4 days after selection. Error bars represent SEM from three different
experiments. Asterisk indicates nonspecific band.
(H) PC3 cells were cotransfected with wild-type or DBM Flag-Ets2, His-ubiquitin (Ub), and HA-PTEN and treated with the proteasome inhibitor MG132 (10 mM) for
4 hr before harvesting. His-Ub-conjugated Ets2 was purified from cell lysates using Ni2+-NTA spin column under denaturing conditions.
(I) Cellular senescence assay of primary Ptenlox/loxMEFs, infected with a retroviral combination of wild-type or Ets2(DBM), CDH1, and Cre as indicated, at 4 days
after selection. Error bars represent SEM from three different experiments.
See also Figure S4.
Cell 144, 187–199, January 21, 2011 ª2011 Elsevier Inc. 193
CA B
%
)
50
100
150
200
250
300
350
400100
80
60
40
20
0
p
m
o
l 
ph
os
ph
at
e 120
140
0
20
40
60
80
100
10 11 12 13B
rd
U
-p
os
iti
ve
 c
el
ls
 (%
Actin
PTEN
AKT
P-AKT
um
or
 v
ol
um
e 
(m
m
3 )
*
#
Vector WT C124S
0
D
IVT-CDH1:
GST-PTEN:
+ + + + + + + +-
-
WT C124S
Time (h) T
u
Time (d)
4 6 8 12 1410
PLK1
Cyclin A2
Aurora A
Geminin
Vector WT C124S
+
-
5
10
15
20
25
30
35
40
45
yc
lin
 B
-U
b 
(D
.U
.) 
WT C124S
A
P
C
 a
ss
ay Cyclin B-Ub
conjugates
PTEN
Actin
AKT
P-AKT
0C
y
GST-PTEN
In
pu
t
35S-Cyclin B
GST-PTEN
IVT-CDH1
Cdh1
-/-
Cdh1
+/+
Cdh1
-/-/CDH1
2
4
6
8
10
12
14
16
18
l  n
um
be
r (
x1
04
)
Cdh1
+/+
/Vector
Cdh1
+/+
/C124S
Cdh1
-/-
/Vector
Cdh1
-/-
/C124S
Cdh1
-/-
/CDH1/Vector
Cdh1
-/-
/CDH1/C124S
Cyclin A2
32P-H1
32P-H1
*
E
Histone H1
(fold)1 0.30 1.88 2.10 1.46 0.46
yc
E 1
C
yc
A 2
0C
el
l
Time (d)
0 1 2 3
CDK2
Cyclin E1
32P-H1
C
D
K
2
C
y
Figure 6. PTEN Regulates APC-CDH1 Independently of Its Phosphatase Activity
(A) diC8-PtdIns(3,4,5)P3 (40 mM) was incubated without (control) and with PTEN (WT), PTEN(C124S), or PTEN(G129E) immunoprecipitates (1 mg) at 37
C for
30 min and then the free phosphate was measured using the Green Reagent. Error bars represent the SEM from three different experiments.
(B) PC3 cells complemented with wild-type or phosphatase-inactive PTEN(C124S) were nocodazole synchronized, released for the indicated times, and pulsed
with BrdU 30min before harvesting. The proportion of BrdU+ cells wasmeasured (left) and cell lysates were subjected to western blot (right). Error bars represent
SEM from three different experiments.
(C) PC3 cells complemented with wild-type or phosphatase-inactive PTEN(C124S) were injected subcutaneously into nude mice. Tumor volume was monitored
(top) and tissue lysates at 2 weeks after injection were subjected to immunoblotting (bottom). Error bars represent SEM (n = 6 mice/group).
(D) Immunopurified APC/C from PC3 cells, released 3 hr post-nocodazole synchronization, were subjected to in vitro ubiquitination assay using 35S-labeled
Cyclin B in the presence of in vitro-translated (IVT)-CDH1 (2 ml) and different amounts of wild-type or PTEN(C124S) proteins (0, 50, 100, 200 ng). Right panel
illustrates the density unit (D.U.) of Cyclin B-Ub conjugates analyzed by the ImageJ 1.383 software.
(E) Growth curves (left) and in vitro kinase assay (right) of immortalized wild-type and Cdh1/MEFs, infected with a retroviral combination of human CDH1 and
PTEN(C124S) (with selection) as indicated and followed over a 3 day period. Error bars represent SEM from three different experiments. The relative kinase
activities were normalized with histone H1 inputs.
Asterisk indicates heavy chain of IgG. See also Figure S5 and Figure S6. p value was determined by Student’s t test (*p < 0.01; #p < 0.05).
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measured by Cyclin B ubiquitination) and in vivo (as measured
by ubiquitination of Cyclin B and Ets2) (Figure 6D and Figures
S6A and S6B). Finally, we found that, like wild-type PTEN, over-
expression of phosphatase-inactive PTEN(C124S) resulted in
a significant growth suppression accompanied with lower
Cyclin A2-associated CDK2 activity in immortalized Cdh1
+/+ (or
Cdh1/ MEFs complemented with human CDH1) but not
Cdh1/ cells (Figure 6E and Figure S6C).
We then investigated the effects of pharmacological inhibition
of PTEN phosphatase activity on APC-CDH1 function. Di-potas-
sium bisperoxo (picolinato) oxovanadate [bpV(Hopic)] inhibits
PTEN phosphatase activity (Lai et al., 2007; Rosivatz et al.,
2006). Coimmunoprecipitation analysis revealed that the treat-
ment of DU145 cells with 1 mM bpV(Hopic) had no effects on
the formation of APC-CDH1 despite strong activation of AKT
(Figure S6D). Additionally, the inhibition of PI3-kinase by treat-
ment with 1 mM LY294002 failed to alter the interaction between
APC3 and CDH1 or the ubiquitin ligase activity of APC-CDH1
(Figure S6E). Taken together, these results demonstrate that
PTEN regulates APC-CDH1 in a phosphatase-independent
manner.
PTEN Loss but Not Inactivation of Its Phosphatase
Activity Results in Hypersensitivity to Pharmacological
Inhibition of APC-CDH1 Targets
Inhibition of APC-CDH1 targets, such as PLK1 or Aurora kinases,
has been pursued as a therapeutic modality to treat human
cancers due to the fact that APC-CDH1 activity is reduced in
tumors (Bassermann et al., 2008; Taylor and Peters, 2008).
Indeed, PLK1 inhibitors as well as Aurora A inhibitors are
currently being evaluated as anticancer agents (Harrington
et al., 2004; Strebhardt and Ullrich, 2006). In our study we have
demonstrated that levels of PLK1 and Aurora A are elevated
upon PTEN loss in both asynchronous and synchronized condi-
tions, suggesting that PTEN-deficient tumors might exhibit
addiction to these kinases and hence hypersensitivity to their
pharmacological inhibition. On the basis of the dispensability
of the phosphatase activity of PTEN, we hypothesized that
PTEN-deficient tumor cells would bemore sensitive to such ther-
apeutic approaches compared to phosphatase-inactive PTEN
mutant cells. To test this hypothesis, we first pharmacologically
inhibited PLK1 in wild-type and PTEN null cells. Both human and
murine Pten null cells were highly sensitive to PLK1 pharmaco-
logical inhibition by BI 2536, a PLK1 inhibitor (Figures 7A and
7B and Figures S7A and S7B; PLK1 inhibition was directly
measured by spindle assembly; Figure S7C). Importantly, the
growth inhibitory effect of BI 2536 in PTEN null cells was associ-
ated with a profound mitotic arrest followed by apoptosis, as
measured by cleavage of Parp and caspase-3 (Cpp32) (Figures
7A, right panel and Figure 7C). Critically, reconstitution of PTEN
null cells with phosphatase-inactive PTEN(C124S) significantly
restored the resistance to pharmacological inhibition of PLK1
(Figures 7B and 7C and Figure S7D). Similarly, PTEN null cells
were hypersensitive to Aurora A inhibition by VX680 (MK0457)
(Figures 7D and 7E and Figures S7E and S7F; Aurora A inhibition
was directly measured by histone H3 phosphorylation on Ser10;
Figure S7G). Of note, Aurora A inhibition by VX680 in PTEN null
cells induced a robust accumulation of >4 N DNA content—asmeasured by flow cytometry—and subsequent apoptosis (Fig-
ure 7D, right panel and Figure 7F). Importantly, the sensitivity
of phosphatase-inactive PTEN(C124S)-expressing cells to
VX680 was similar to that of wild-type PTEN-expressing cells
(Figures 7E and 7F and Figure S7H). Taken together, these
data suggest that PTEN loss but not phosphatase inactivation
results in hypersensitivity to pharmacological inhibition of APC-
CDH1 targets PLK1 and Aurora A.
DISCUSSION
Our findings allow us to reach a number of relevant conclusions.
First, we have identified a novel mechanism by which PTEN
exerts its tumor-suppressive function within the nucleus by regu-
lating the assembly and activity of APC-CDH1. Whereas high
concentrations of nuclear PTEN are associated with G0/G1
phase and differentiated cells, lower concentrations of nuclear
PTEN level are observed during S phase and in highly prolifer-
ating advanced tumors (Gimm et al., 2000; Ginn-Pease and
Eng, 2003; Perren et al., 2000). Furthermore, Pten and Cdh1
are haploinsufficient tumor suppressors in the mouse and
their heterozygous loss leads to diverse cancers, including
cancers of the prostate and breast (Garcia-Higuera et al.,
2008; Salmena et al., 2008). By contrast, complete acute loss
of either tumor suppressor triggers a cellular senescence
response (Chen et al., 2005; Li et al., 2008). In this study, we
have demonstrated that Pten-loss-induced senescence is
dependent on the Cdh1/Ets2/p16 pathway. On the basis of these
data, we propose that PTEN loss elicits a potent senescence
response through both phosphatase-dependent (superactiva-
tion of a PI3K/mTOR/p53 pathway; Alimonti et al., 2010; Chen
et al., 2005) and phosphatase-independent (loss of APC-CDH1
function, unrelated to Arf or p53/p21 pathways) activities, in
turn highlighting the complexity of the dose-dependent tumor-
promoting and fail-safe cellular responses evoked by PTEN
loss (Figure 7G).
Second, we find that the novel function of nuclear PTEN pre-
sented herein is independent of its phosphatase activity. Cyto-
plasmic but not nuclear pools of PIP3 are sensitive to catalysis
by PTEN, implying a potential role for nuclear PTEN beyond its
phosphatase activity (Lindsay et al., 2006). Indeed, growth-inhib-
itory effects of nuclear PTEN are likely not mediated directly
through the PI3K/AKT pathway (Blanco-Aparicio et al., 2007;
Liu et al., 2005). Given that APC3 is highly phosphorylated on
multiple residues in mitosis (Kraft et al., 2003), one could suspect
that PTEN may be a potential phosphatase for APC3. However,
in mitotic cells, we did not observe dephosphorylation of APC3
by PTEN neither in vivo nor in vitro (M.S.S. and P.P.P, unpub-
lished data), and in addition, a catalytically inactive form of
PTEN is fully functional toward APC. Overall, the phosphatase-
independent activity of nuclear PTEN toward APC-CDH1
provides a straightforward explanation for the remnant tumor-
suppressive activity associated with the phosphatase-inactive
PTEN(C124S) mutation.
Finally, we have demonstrated that PTEN-deficient and PTEN
mutant cancer cells are differentially sensitive to pharmacolog-
ical inhibition of PLK1 and Aurora A. Thus, our study indicates
that patients with cancers harboring complete PTEN loss mayCell 144, 187–199, January 21, 2011 ª2011 Elsevier Inc. 195
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Figure 7. PTEN Loss but Not Phosphatase Inactivation Results in Hypersensitivity to Pharmacological Inhibition of APC-CDH1 Targets
(A) Growth inhibition of immortalized wild-type and Pten/MEFs treated with the PLK1 inhibitor BI 2536 (50 nM) for 48 hr was measured (left). Western blots of
cell lysates after BI 2536 treatment for 48 hr are shown on the right. Error bars represent SEM from three different experiments.
(B) Growth inhibition of PC3 cells complemented with wild-type or PTEN(C124S) and treated with the PLK1 inhibitor BI 2536 (5 nM) was measured after the 48 hr
treatment. Error bars represent SEM from three different experiments.
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benefit from pharmacological targeting of the APC-CDH1
pathway, whereas we predict mutant PTEN tumors to be much
less sensitive. The APC-CDH1 targets PLK1 and Aurora kinases
are overexpressed in human tumors, and this has prognostic and
therapeutic potential in cancers (Meraldi et al., 2004; Strebhardt
and Ullrich, 2006). Clinical trials in cancer patients are currently
underway to test the effects of various PLK1 and Aurora A inhib-
itors as monotherapy or in combination with conventional
chemotherapy. For example, phase II trials of BI 2536 in
advanced small cell lung carcinoma (SCLC), non-small cell
lung carcinoma (NSCLC), and acute myeloid leukemia (AML)
and phase II trials of VX680 (MK0457) in chronic myeloid
leukemia (CML) are currently ongoing (weblink: http://www.
cancer.gov). It has been recently reported that oncogenic Ras
activation engages the cells to be hypersensitive (synthetic
lethal) to various mitotic inhibitors including BI 2536 (Luo et al.,
2009). By contrast, and in full agreement with our findings, onco-
genic PI3K activation does not respond to PLK1 inhibition, sug-
gesting that PTEN-loss-driven hypersensitivity to inhibition of
PLK1 and Aurora A is unlikely due to the PI3K/AKT pathway
(Luo et al., 2009). Hence, our findings provide a rationale for
cancer patient stratification based on PTEN loss versus PTEN
mutation toward the optimization of targeted therapies. This
principle is of great importance given the widespread incidence
of these two states of PTEN gene disruption in human cancer.
Furthermore, because the functions of PTEN toward PI3K/AKT
signaling and the APC-CDH1 pathway are uncoupled, it is
tempting to speculate that combinatorial therapy with PLK1/
Aurora kinases and PI3K/mTOR inhibitors may be an effective
approach in PTEN null cancers.
EXPERIMENTAL PROCEDURES
Reagents and Antibodies
Chemical reagents are from Sigma unless otherwise described. G418, puro-
mycin, and hygromycin, which are used for establishment of stable cell lines,
are purchased from Invitrogen. BrdU and anti-BrdU antibody were from BD
Biosciences. The PLK1 inhibitor BI 2536 and the Aurora A inhibitor VX680
were from Chemie Tek. All the sources of antibodies used are listed in the
Extended Experimental Procedures.
Mass Spectrometry
PTEN-deficient PC3 cells transfected with pRK5-Myc-PTEN were subjected
to cellular fractionation. The details of nuclear fractionation method are
described in the Extended Experimental Procedures. The nuclear extracts
were immunoprecipitated with anti-Myc antibody and the PTEN-associated
proteins were eluted with Myc peptide. The eluates were resolved by SDS-
PAGE on 4%–12% gradient gel (Invitrogen) for silver staining (Pierce). Specific(C) The cell population inmitosis of PC3 cells complementedwith wild-type or PTE
with anti-phospo-histone H3 (P-H3(pS10)) (left) and quantified for a 48 hr period
(D)Pten null cells are hypersensitive to Aurora A inhibition. Growth inhibition of imm
(500 nM) was measured after the 48 hr treatment (left). Western blots of cell lysate
on the right. Error bars represent SEM from three different experiments.
(E) Growth inhibition of PC3 cells complemented with wild-type or PTEN(C124S)
48 hr treatment. Error bars represent SEM from three different experiments.
(F) The cell population harboring >4NDNA content of PC3 cells complemented w
flow cytometry (left) and quantified for a 48 hr period (right). Error bars represent
(G) A proposed model for phosphatase-independent role of nuclear PTEN towar
See also Figure S7. p values were determined by Student’s t test (*p < 0.01; #p >bands were cut out from the gel and subjected to mass-spectrometric peptide
sequencing.
Immunoprecipitation and In Vitro Binding Assay
The details of immunoprecipitation and in vitro binding assay are described in
the Extended Experimental Procedures.
In Vitro Ubiquitination Assay
The APC/C or PTEN was immunopurified with anti-APC3 (Sigma) or anti-PTEN
(Cell Signaling) antibody, respectively, from PC3, DU145, wild-type, and
Pten/ MEFs subjected to nocodazole synchronization and release for 2 or
3 hr. The ubiquitin ligase activity of APC-CDH1 complex was performed as
described in detail in the Extended Experimental Procedures.
In Vivo Ubiquitination Assay
PC3 cells were cotransfected with pCS2-6Myc-Cyclin B (wild-type or DBM),
provided by H. Yu, GFP-PTENWT or -PTENK13,289E, and HA-ubiquitin (Ub).
Alternatively, cells were transfected with a combination of His-Ub and wild-
type or DBM Ets2, provided by P. Zhang (Li et al., 2008). The details of
in vivo ubiquitination assay are described in the Extended Experimental
Procedures.
Cell Culture and Flow Cytometry
Primary MEFs and PC3 cells complemented with wild-type or phosphatase-
inactive PTEN(C124S) were established and maintained as described in the
Extended Experimental Procedures. The details of cell-cycle analysis by
flow cytometry are also described in the Extended Experimental Procedures.
siRNA and shRNA
All the sources of siRNAduplexes and shRNA constructs used are described in
the Extended Experimental Procedures.
PtdIns(3,4,5)P3 Phosphatase Assay
We purchased diC8-PtdIns(3,4,5)P3 and the Green Reagent from Echelon and
Biomol, respectively. Measurement of phosphate released from the substrate
was performed according to the manufacturer’s instructions and is described
in detail in the Extended Experimental Procedures.
In Vitro Kinase Assay
The immunoprecipitates with Cyclin A2, Cyclin E1, or CDK2 prepared from cell
lysates were incubated with histone H1 (Roche) and [g-32P]ATP (PerkinElmer)
for 30min at room temperature. Reactionmixture was resolved by SDS-PAGE,
and then phosphorylated histone H1 was analyzed by SDS-PAGE and
autoradiography.
Cell Proliferation and Senescence Assay
Typically, cell proliferation and senescence assays were performed as
described (Chen et al., 2005), and the details of methods are described in
the Extended Experimental Procedures. For cell proliferation assays with the
PLK1 inhibitor BI 2536 (Lenart et al., 2007; Steegmaier et al., 2007) or the
Aurora A inhibitor VX680 (Harrington et al., 2004), SV40-LT-immortalized
wild-type and Pten/ MEFs or PC3 cells complemented with wild-type or
PTEN(C124S) were incubated in the presence of the indicated concentrationsN(C124S) and treated with 5 nMBI 2536was analyzed by immunofluorescence
(right). Error bars represent SEM from three different experiments.
ortalizedwild-type andPten/MEFs treatedwith the Aurora A inhibitor VX680
s after the treatment with different concentrations of VX680 for 48 hr are shown
and treated with the Aurora A inhibitor VX680 (500 nM) was measured after the
ith wild-type or PTEN(C124S) and treated with VX680 (500 nM) was analyzed by
SEM from three different experiments.
d APC-CDH1 to regulate proliferation and cellular senescence.
0.05).
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of BI 2536 or VX680 (Chemie Tek) at a 48 hr period, and then cell growth was
measured.
Mouse Xenograft Tumor Model
PC3 cells complemented with wild-type or PTEN(C124S) (1 3 107 cells per
site) in suspension were mixed with equal volumes of matrigel (BD Bioscience)
and injected subcutaneously into 6-week-old male nude mice (Charles River
laboratory). Measurement of tumor size was performed twice a week, and
tumor volume was estimated using the following formula: volume = length 3
width2 3 0.526.
RNA Isolation and Quantitative Real-Time RT-PCR
Total RNAwas isolated with Trizol reagent (Invitrogen) and reverse-transcribed
with the Superscript III reverse transcriptase (Invitrogen). Expression of
specific mRNAs was determined with the LightCycler (Roche) using the
SYBR Green PCR Master Mix (QIAGEN). All the sources of quantitative real-
time RT-PCR primers used are listed in the Extended Experimental
Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures and
seven figures and can be found with this article online at doi:10.1016/j.cell.
2010.12.020.
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